Clinical pharmacokinetics of propranolol
- PMID: 378502
- DOI: 10.2165/00003088-197904020-00001
Clinical pharmacokinetics of propranolol
Abstract
Propranolol is completely absorbed after oral administration and widely distributed throughout tissues. Elimination occurs almost wholly by metabolic transformation in the liver and excretion of the resultant products in the urine. An active metabolite, 4-hydroxypropranolol and possibly other active compounds have been identified; the former only after oral administration. After intravenous administration, hepatic extraction is so efficient that drug clearance is dependent on liver blood flow. After oral administration, propranolol kinetics depend on both dose and duration of therapy, but hepatic extraction remains relatively high and leads in presystemic ('first-pass') elimination and low systemic availability. During continued administration, plasma concentrations vary quite widely due to genetic differences superimposed on which are certain constitutional factors, such as age, and environmental factors such as smoking, other drugs, and perhaps diet. Hepatic, renal, thyroid and some gastrointestinal diseases as well as hypertension, malnutrition and hypothermia may be associated with alterations in propranolol disposition, all of which are consistent with the pathophysiology of these diseases.
Similar articles
-
Interaction between oral propranolol and hydralazine.Clin Pharmacol Ther. 1980 Jun;27(6):726-32. doi: 10.1038/clpt.1980.103. Clin Pharmacol Ther. 1980. PMID: 7379440
-
No stereoselective first-pass hepatic extraction of propranolol.Clin Pharmacol Ther. 1981 Sep;30(3):291-6. doi: 10.1038/clpt.1981.162. Clin Pharmacol Ther. 1981. PMID: 7273593
-
Pharmacokinetics of propranolol: a review.Postgrad Med J. 1976;52 Suppl 4:22-25. Postgrad Med J. 1976. PMID: 787953 Review.
-
Direct measurement of propranolol bioavailability during accumulation to steady-state.Br J Clin Pharmacol. 1978 Oct;6(4):345-50. doi: 10.1111/j.1365-2125.1978.tb00862.x. Br J Clin Pharmacol. 1978. PMID: 698031 Free PMC article.
-
Clinical pharmacokinetics of verapamil.Clin Pharmacokinet. 1984 Jan-Feb;9(1):26-41. doi: 10.2165/00003088-198409010-00002. Clin Pharmacokinet. 1984. PMID: 6362951 Review.
Cited by
-
A comparative pharmacokinetic study of conventional propranolol and long acting preparation of propranolol in patients with cirrhosis and normal controls.Br J Clin Pharmacol. 1987 Oct;24(4):527-35. doi: 10.1111/j.1365-2125.1987.tb03207.x. Br J Clin Pharmacol. 1987. PMID: 3689632 Free PMC article.
-
Relationship between dose, blood level and haemodynamic response in patients with cirrhosis receiving propranolol.Eur J Clin Pharmacol. 1985;28(3):353-5. doi: 10.1007/BF00543337. Eur J Clin Pharmacol. 1985. PMID: 4007042
-
Transdermal controlled delivery of propranolol from a multilaminate adhesive device.Pharm Res. 1989 Sep;6(9):753-8. doi: 10.1023/a:1015967329033. Pharm Res. 1989. PMID: 2813272
-
Human pharmacokinetic and pharmacodynamic studies on Ro31-1118, a new beta-adrenoceptor antagonist.Br J Clin Pharmacol. 1985 Mar;19(3):319-27. doi: 10.1111/j.1365-2125.1985.tb02650.x. Br J Clin Pharmacol. 1985. PMID: 2859047 Free PMC article. Clinical Trial.
-
Evaluation of a radioreceptor assay for beta-adrenoceptor antagonists in plasma.Eur J Clin Pharmacol. 1980 May;17(5):349-54. doi: 10.1007/BF00558447. Eur J Clin Pharmacol. 1980. PMID: 6106550
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources